内容紹介
Two Cases of Thymic Carcinoid Treated with Octreotide Long-Acting Repeatable
Summary
Thymic carcinoid is a rare disease that accounts for 3.1% of thymic tumors and 1.8-6% of all carcinoid tumors in Japan. Advanced thymic carcinoid has a 5-year survival rate of 28-31%. Compared with carcinoid tumors that arise in other organs, thyroid carcinoid tumors carry a relatively worse prognosis, and the most effective therapeutic strategy is thought to be surgical resection. However, for patients with recurrence and distant metastases, multimodal therapy including radiotherapy and/or chemotherapy is usually applied. No chemotherapy treatment regimen has been established in Japan, although the National Comprehensive Cancer Network Guidelines proposed the application of octreotide long-acting repeatable(LAR). In this report, we present two cases of thymic carcinoid that were treated with octreotide LAR and achieved long-term survival.
要旨
胸腺カルチノイドはわが国の胸腺腫瘍の約3.1%を占める比較的まれな疾患であるが,5年生存率は28～31%と不良であり,しばしば治療に難渋する。治療は外科的切除が中心だが,再発,遠隔転移症例では化学療法や放射線療法が行われる。ただし,有効性が確立された化学療法はない。一方でNational Comprehensive Cancer Network(NCCN)のガイドラインでは,化学療法としてオクトレオチドlong acting repeatable(LAR)の有効性が明記されている。今回われわれは,胸腺カルチノイド症例に対してオクトレオチドLAR療法を行い,比較的長期にわたり生存が得られた2症例を経験したので報告する。
目次
Summary
Thymic carcinoid is a rare disease that accounts for 3.1% of thymic tumors and 1.8-6% of all carcinoid tumors in Japan. Advanced thymic carcinoid has a 5-year survival rate of 28-31%. Compared with carcinoid tumors that arise in other organs, thyroid carcinoid tumors carry a relatively worse prognosis, and the most effective therapeutic strategy is thought to be surgical resection. However, for patients with recurrence and distant metastases, multimodal therapy including radiotherapy and/or chemotherapy is usually applied. No chemotherapy treatment regimen has been established in Japan, although the National Comprehensive Cancer Network Guidelines proposed the application of octreotide long-acting repeatable(LAR). In this report, we present two cases of thymic carcinoid that were treated with octreotide LAR and achieved long-term survival.
要旨
胸腺カルチノイドはわが国の胸腺腫瘍の約3.1%を占める比較的まれな疾患であるが,5年生存率は28～31%と不良であり,しばしば治療に難渋する。治療は外科的切除が中心だが,再発,遠隔転移症例では化学療法や放射線療法が行われる。ただし,有効性が確立された化学療法はない。一方でNational Comprehensive Cancer Network(NCCN)のガイドラインでは,化学療法としてオクトレオチドlong acting repeatable(LAR)の有効性が明記されている。今回われわれは,胸腺カルチノイド症例に対してオクトレオチドLAR療法を行い,比較的長期にわたり生存が得られた2症例を経験したので報告する。